GLP-1 Peptide Atlas, by Delfa

RecruitingPhase NA

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Assets

GLP-1 / incretin class catch-all / Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•DNA methylation-based biological age

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07293325

Org study ID2025-0568

Timeline

Milestones

Study start2025-06-02actual

Study first posted2025-12-19actual

Last update posted2025-12-19actual

Primary completion2027-04-02estimated

Study completion2027-06-02estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all Semaglutide Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

1. Adults aged 18 to 75 years.

2. Diagnosed with simple obesity, defined as BMI ≥ 30 kg/m².

3. Have not used any anti-obesity medications (including GLP-1 RAs, tirzepatide, metformin for weight loss, etc.) within the past 3 months.

4. Able and willing to comply with study procedures and complete follow-up assessments.

5. Provide written informed consent.

Exclusion criteria

1. Presence of secondary obesity (e.g., endocrine disorders such as Cushing's syndrome or hypothyroidism).

2. Use of anti-obesity medications or participation in another weight-loss program within the past 3 months.

3. Diagnosed type 1 or type 2 diabetes mellitus requiring hypoglycemic drug therapy.

4. History of pancreatitis, severe gastrointestinal disease, or bariatric surgery.

5. Severe cardiovascular, hepatic, renal, or psychiatric disease that may affect participation.

6. Pregnant or breastfeeding women, or women planning pregnancy during the study period.

7. Current participation in any other clinical trial.

8. Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Change in DNA methylation-based biological age measured by iWatchAge

Time frame:Baseline and Week 24

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.